Study finds immune markers at two months tied to longer survival in glioblastoma trial

Researchers at The University of Texas MD Anderson Cancer Center have identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus, Delta-24-RGD, that targets and eliminates cancer cells.